Biomedical subjects
Publications and source records attributed to E Nakajima.
Hepatobiliary studies on five patients with Dubin-Johnson syndrome were performed using 99mTc-PMT. Time-activity curves of the liver of the patients showed delayed excretion and that plasma elimination in the patients was prolonged compared to that of normal subjects.
Immunoglobulin M antibody to hepatitis B core antigen (IgM anti-HBc) was measured by radioimmunoassay in the sera of 96 HBV carriers. IgM anti-HBc was detected in 17 of 66 patients with chronic active hepatitis and in 4 of 11 with liver cirrhosis. This antibody was not present in asymptomatic carriers or in patients with chronic persistent hepatitis. Testing of sequential samples revealed that the presence of IgM anti-HBc indicated active replication of HBV and at the same time an immune response to the virus. The relationship between IgM anti-HBc and the response to interferon (IFN) therapy was also studied. Results showed that IgM anti-HBc is a useful marker of the efficacy of interferon therapy.
In order to determine the relationship between structure and distribution in mono-quaternary ammonium ions, the distribution of a series of 14C-labeled tetraalkylammonium and substituted trimethylanilinium ions in mice were comparatively studied by means of whole-body autoradiography and radioassay. The partition coefficient in n-octanol/water were also determined. With tetraalkylammonium, the concentration in blood and tissues decreased in the order of tetramethyl, tetraethyl and tetrapropylammonium, which was opposite to expectation based on their partition coefficient values, but was in the order of increasing steric hindrance at the cationic head. With substituted trimethylanilinium, the concentrations in the blood, skeletal and cardiac muscles, diaphragm and salivary gland after i.v. injection to mice increased in the order: m-NO2 less than Cl less than OCH3 less than H less than CH3. This did not coincide with the order of increasing the partition coefficients, but coincided with the decrease of the Hammett sigma-constants of the substituent. These results were interpreted on the basis of the assumption that the ion-pair formation of the cationic head with an anionic site of the tissue macromolecules played an important role in determining distribution. It was pointed out that although the lipophilic character of the molecule has been often cited as the most important factor determining the distribution of the drugs, the ionic character of the molecule or of the functional group can participate as a more important factor in determining tissue distribution.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A new dosage form of levodopa, which has the characteristics of loading high concentrations of levodopa at the upper part of the intestine, has been developed to improve its bioavailability. It is shown that an effervescent tablet formulation, coated with hydroxypropyl methylcellulose phthalate (carboxybenzoyl radical content: 20-24%) as the enteric material, is suitable for the purpose of dissolution. This was confirmed from animal experiments, which showed that tablets of this composition disintegrate instantly on reaching the upper part of the intestine. This tablet was considered appropriate for the bioavailability tests described in this paper.
The distribution of mercury in the brain of mice after i.v. administration of methylmercury, methylmercury with selenite, or bis(methylmercuric) selenide (BMS) was examined by whole-body autoradiography using 203Hg-labelled mercury compounds. The radioactivity in the brain of the mice that received methylmercury and selenite simultaneously, or BMS, was higher than that of the mice that received methylmercury alone, but the differences were not significant.
The bioavailabilities of five commercially available flufenamic acid (FA) capsules were studied in humans and beagle dogs. The dissolution rates of these capsules were determined by several methods. Experiments on in vitro/in vivo and humans/dogs correlations were performed to evaluate the dissolution test methods and the values of beagle dogs as models for predicting bioavailability of weak acid drugs in humans. Significant differences in the rates and extents of bioavailability of the different capsules were observed both in humans and dogs, but results in humans differed from those in dogs. The dissolution rates, determined by dissolution methods involving pretreatment with acidic solutions, correlated significantly with bioavailabilities in humans and dogs; however, those obtained by the rotating basket and paddle methods without any surface active agents did not correlate with in vivo data.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Several potential mechanisms for reduced levodopa bioavailability following oral administration to dogs and humans were investigated by studying the influence of the administration route on plasma levodopa levels after intravenous, hepatoportal, and duodenal administrations to dogs. The observed average areas under the plasma concentration-time curves (AUC) of levodopa following hepatoportal injection and intravenous injection were virtually identical; but following duodenal administration a decrease in the AUC of levodopa was observed with a concomitant increase in the AUC of total dopamine. The possible involvement of intestinal microorganisms in levodopa metabolism was explored in dogs that had been administered a combination of paromomycin and kanamycin to reduce intestinal microflora. Similar patterns of plasma level profiles and urinary excretion were observed between control and treated dogs. As measured by the release of [14C]carbon dioxide from [14C]levodopa, the distribution of levodopa decarboxylase enzyme activity in various parts of the intestine was studied in homogenates prepared from isolated intestinal segments of the duodenum and upper, middle, and lower parts of the jejunum and ileum. The jejunum showed the highest decarboxylase activity followed by the ileum and duodenum. These data indicate that the reduced bioavailability of orally administered levodopa occurs as a result of metabolism by levodopa decarboxylase enzyme in the gut wall.
Plasma levels of levodopa, total dopamine, and residual amounts of levodopa and its metabolites at the administered site were analyzed following administration of single 100-mg doses of levodopa in solution into isolated segments of the duodenum, jejunum, and ileum of the dog. The largest area under the plasma concentration-time curve (AUC) of levodopa during the 1.0-hr study was obtained following administration in the duodenum, followed by the jejunum and ileum. In addition, the residual amounts of levodopa and its metabolites detected at the administration sites were: ileum, 23%; jejunum, 7% and duodenum, less than 1%. The largest AUC of total dopamine was obtained following administration in the jejunum, followed by the ileum and duodenum. This order was consistent with the order of levodopa decarboxylase enzyme activity reported previously. Therefore, it can be concluded that the major absorption site of levodopa in the intestine resides in the upper small intestine. Levodopa in 10-, 50-, and 100-mg doses was administered into isolated duodenal segments. The AUC of levodopa increased nonlinearly with increasing dose. Negligible amounts of both levodopa and its metabolites were observed in the segment at 1.0 hr after administration, indicating that the duodenal absorption of levodopa was not saturable within the dose range tested.
Intracellular transport and secretion of fibroin in the posterior silk gland cells of the silkworm, Bombyx mori, were investigated in relation to the radial microtubule and circular microtubule-microfilament systems of the cells. The silk glands were pulse-labelled for 3 min with [3H]glycine in vitro and then chased in media containing excess cold glycine and in some cases antimitotic reagents (colchicine or vinblastine) or cytochalasin (B or D), and the flow of the label in the glands was investigated by radioautography. It was revealed that the label initially located over the rough endoplasmic reticulum subsequently moves to the Golgi bodies to be condensed there. The secretory granules of fibroin or fibroin globules thus formed are transported via the radial microtubule system to the apical cytoplasm to be secreted there under some regulation by the circular microtubule-microfilament system. In the presence of colchicine or vinblastine, the secretion of fibroin was suppressed an marked accumulation of fibroin globules in the Golgi regions was observed, while in the presence of cytochalasin B or D the secretion was accelerated and extensive invagination of the luminal surface, which was probably due to the serial exocytosis of fibroin globules, was observed. These results suggest that the radial microtubule system and the circular microtubule-microfilament system are responsible for intracellular transport of fibroin globules from Golgi bodies to the apical cytoplasm and secretion by exocytosis at the luminal surface, respectively.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
To estimate the absolute bioavailability of oral levodopa, plasma concentrations and urinary excretion of levodopa and its metabolites were determined in beagle dogs and in parkinsonian patients after intravenous and oral drug administration. The absolute bioavailability of orally administered levodopa was estimated to be about 35% in both dogs and patients; however, the total amount absorbed of intact drug and levodopa metabolites was estimated to be 80--90% of the administered dose. Due to the similarities of the pharmacokinetic characteristics of levodopa found in beagle dogs and in humans, beagle dogs can serve as a model to study bioavailability, absorption, and metabolic mechanisms.
The relationship between the dose of levodopa and its pharmacokinetic behavior following intravenous and oral administration was investigated in dogs and parkinsonian patients. Six beagle dogs received single doses of 2.4, 4.8, and 9.6 mg of levodopa/kg iv and single doses of 4.8, 9.6, and 19.2 mg of levodopa/kg po in a crossover fashion on separate occasions. Three parkinsonian patients received single oral doses of approximately 3.8, 7.7, and 15.4 mg of levodopa/kg in a crossover test. Plasma samples were analyzed for intact levodopa and total dopamine. The relationship between the area under the plasma concentration-time curve (AUC) of levodopa and the intravenous dose to dogs was linear. However, in both dogs and patients, the relationship after oral dosing was nonlinear, with the relative AUC increasing with increasing dose. Therefore, the pharmacokinetic behavior of levodopa after oral administration to dogs and patients was dose dependent.